Tyra Biosciences is offering 9,079,000 common shares and pre-funded warrants for 9,078,529 shares at prices of $22.0300 and $22.0290, respectively, for a total offering price of $400,001,285.34. The financing supports IR NMIBC, achondroplasia, preclinical work and corporate purposes, while the prospectus shows $11.45 dilution per share.

Key Highlights

  • Each pre-funded Warrant carries a $0.001 exercise price and may be exercised after issuance, subject to an ownership limitation.
  • The filing lists $376,000,663.51 in proceeds before expenses after Underwriting discounts and commissions.
  • The offering represents immediate dilution of $11.45 per share for participating investors under the prospectus calculations.

The offering prices are $22.0300 per share and $22.0290 per pre-funded warrant, producing a total offering price of $400,001,285.34. Tyra Biosciences (NASDAQ: TYRA) is the issuer and delivery was expected on or about September 15, 2026.

Pre-Funded Warrants

The pre-funded warrants are available to certain investors instead of common stock. Their purchase price is $0.001 below the common-stock offering price, and each warrant carries a $0.001 exercise price per share. Warrants may be exercised at any time after issuance, subject to an ownership limitation.

Underwriting Discounts and Proceeds

Underwriting discounts and commissions are $1.3218 per common share and $1.3218 per pre-funded warrant. The total underwriting discounts and commissions are $24,000,621.83. The filing lists $20.7082 per common share and $20.7072 per pre-funded warrant in proceeds before offering expenses, after those deductions. The aggregate proceeds before expenses are $376,000,663.51. The underwriters are Jefferies, Guggenheim Securities, Cantor, Barclays, William Blair, Wedbush, PacGrow, Raymond James and Oppenheimer & Co. Dealers may receive a concession of up to $0.7931 per common share and $0.7931 per pre-funded warrant.

Tyra Biosciences plans to use the proceeds for its IR NMIBC and achondroplasia programs.

Dilution And Future Issuance

The prospectus calculations use 59,662,877 shares outstanding as of June 30, 2026. They also exclude 6,381,950 shares issuable upon exercise of outstanding pre-funded warrants, which have an exercise price of $0.001 per share, plus 4,189,420 shares reserved under the 2021 Incentive Award Plan and the 2021 Employee Stock Purchase Plan. The prospectus calculates an immediate $4.65 per-share increase in net tangible Book Value for existing stockholders and $11.45 per-share dilution for investors participating in the offering. A separate sales agreement with TD Securities (USA) LLC allows Tyra Biosciences to issue and sell up to $250.0 million of common stock. The full $250.0 million remained available under that agreement as of September 14, 2026.